Recent advances in the management of nasopharyngeal carcinoma
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Over the last few years, certain areas in the management nasopharyngeal carcinoma (NPC) that have an impact on the care of these patients have evolved, particularly with regard to liquid biopsies, minimally invasive surgery, and advances in chemotherapy and immunotherapy. Beyond its proven role in the diagnostics, surveillance, and treatment of NPC, liquid biopsy with plasma Epstein–Barr virus DNA in the screening of high-risk populations for NPC is strongly supported by recent evidence. Surgery of the nasopharynx is reserved for locally recurrent NPC, and in recent years there have been great strides in minimally invasive techniques with survival rates similar to those of open techniques in treating NPC. Induction chemotherapy in a recent pooled analysis was shown to be superior to concurrent chemotherapy alone for locoregionally advanced NPC. Finally, immunotherapy with a PD-1 inhibitor in NPC has been shown to have 1-year overall survival rates comparable to those of other patients with heavily pre-treated metastatic or recurrent NPC. In this commentary, we discuss these recent advances and their potential in the clinical management of patients with NPC.
出版社接受日期12.11.2018
著者Lam W.K.J., Chan J.Y.K.
期刊名稱F1000Research
出版年份2018
月份11
卷號7
出版社NLM (Medline)
文章號碼1829
國際標準期刊號2046-1402
電子國際標準期刊號1759-796X
語言英式英語
關鍵詞EBV DNA, immunotherapy, endoscopic surgery, nasopharyngectomy, Nasopharyngeal carcinoma, robotic surgery

上次更新時間 2020-15-10 於 01:15